Clinical Trial

Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is phase 2 trial of neoadjuvant therapy and short-course radiotherapy in resectable rectal cancer.
Protocol Amendment History 3 changes
notable Enrollment increased: 54 -> 64 participants 2026-07-02
notable Primary completion pushed: 2028-01-31 -> 2030-01-31 2026-07-02
minor Completion moved earlier: 2033-01-31 -> 2032-01-31 2026-07-02
Trial Details
NCT Number NCT04643366
Lead Sponsor Virginia Commonwealth University
Conditions Rectal Cancer
Enrollment 64 participants
Start Date 2021-01-28
Primary Completion 2030-01-31 (estimated)
Study Completion 2032-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-01